Abstract
Innate lymphoid cells (ILCs) are key organizers of tissue immune responses and regulate tissue development, repair, and pathology. Persistent clinical sequelae beyond 12 weeks following acute COVID-19 disease, named post-COVID syndrome (PCS), are increasingly recognized in convalescent individuals. ILCs have been associated with the severity of COVID-19 symptoms but their role in the development of PCS remains poorly defined. Here we used multiparametric immune phenotyping, finding expanded circulating ILC precursors (ILCPs) and concurrent decreased group 2 innate lymphoid cells (ILC2s) in PCS patients compared to well-matched convalescent control groups at > 3 months after infection. Patients with PCS showed elevated expression of chemokines and cytokines associated with trafficking of immune cells (CCL19/MIP-3b, FLT3-ligand), endothelial inflammation and repair (CXCL1, EGF, RANTES, IL1RA, PDGF-AA). These results define immunological parameters associated with PCS and might help find biomarkers and disease-relevant therapeutic strategies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Post-COVID LMU research project is financially supported by the Bavarian State Ministry for Health and Care and the Bavarian State Office for Health and Food Safety (LGL). There is a close link to the nationwide research project "Network University Medicine" (NUM), funded by the Federal Ministry of Education and Research (BMBF) (funding code: 01KX2021) and the NUM-associated research projects. JR is supported by the German Center for Infection Research (DZIF) and Else Kroener-Fresenius-Stiftung (EKFS). JSK received funding from the German Research Foundation (DFG, Deutsche Forschungsgemeinschaft), the German Diabetes Society (DDG, Deutsche Diabetes Gesellschaft), and FoeFoLe, LMU Munich. JSK is also supported by the German Society of Internal Medicine (DGIM, Deutsche Gesellschaft fuer Innere Medizin, Clinician Scientist Program).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
KoCo19 Shield: The study protocol was reviewed and approved by the Institutional Review Board of the Medical Faculty at Ludwig-Maximilians-University Munich, Germany under the project number 20-692 (vote of approval dated Sept. 21st, 2020) and 20-371 (vote of approval dated May 15th, 2020). Oral and written informed consent was obtained from all study subjects. PCC: The study protocol was reviewed and approved by the Institutional Review Board of the Medical Faculty at Ludwig-Maximilians-University Munich, Germany under the project number 21-1165 (vote of approval dated Feb 15, 2021, amendment approved Aug. 11, 2021). Oral and written informed consent was obtained from all study subjects.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Abbreviations
- EFG
- epidermal growth factor
- FLT-3 Ligand
- Fms-related tyrosine kinase 3 ligand
- IF-γ
- interferon γ
- ILC
- Innate lymphoid cells
- ILCP
- Innate lymphoid cell precursors
- ILC2s
- Group 2 innate lymphoid cells
- IL
- interleukin
- IL1RA
- interleukin-1 receptor antagonist
- PBMCs
- Peripheral blood mononuclear cells
- PAIS
- Post-acute infection syndromes (PAIS)
- PC
- Post-Covid
- PCS
- Post-COVID-Syndrome
- PDGF-AA
- platelet-derived growth factor A
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus 2
- TNF
- tumor necrosis factor
- t-SNE
- t-distributed stochastic neighbor embedding
- VEGF
- vascular endothelial growth factor
